Eli Lilly’s IXORA-R study

Eli Lilly (LLY) announced in a press release on September 10 that the company has initiated the IXORA-R head-to-head (or H2H) study evaluating the superiority of drugs Taltz (ixekizumab) and Tremfya (guselkumab) in patients with moderate-to-severe plaque psoriasis. The below chart shows key highlights for the IXORA-R H2H trial.

Eli Lilly Initiates New Trial for Taltz in Plaque Psoriasis

About IXORA-R study

The IXORA-R trial is the first head-to-head trial between interleukin-17 (or IL-17) and interleukin-23 (or IL-23). The study is a 24-week multicenter, randomized, parallel group, and blinded study that compares the safety and efficacy of Eli Lilly’s (LLY) drug Taltz and Janssen Biotech’s (JNJ) drug Tremfya in patients with moderate-to-severe plaque psoriasis. The study aims to enroll 960 patients.

The primary endpoint for the study is based on the psoriasis area severity index 100 score (or PASI 100) and is the proportion of patients with 100% improvement from their baseline at week 12 as measured by PASI 100.

The secondary endpoints for the study are as follows:

  • patients achieving PASI 75 at week two and PASI 100 at week four, eight, and 24
  • patients achieving a zero score of Static Physician Global Assessment at week 12

Eli Lilly expects to complete the study by the end of 2019.

About Taltz

Taltz is approved for the treatment of patients with active psoriatic arthritis and the treatment of moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Taltz’s safety profile has been evaluated in 12 clinical trials in moderate-to-severe plaque psoriasis and four clinical trials in psoriatic arthritis.

Another study, SPIRIT H2H, is evaluating Taltz with AbbVie’s (ABBV) drug Humira (adalimumab) for the treatment of psoriatic arthritis and is expected to be completed in early 2019.

The Healthcare Select Sector SPDR ETF (XLV) holds 2.8% in Eli Lilly (LLY), 10.2% in Johnson & Johnson (JNJ), 4.0% in AbbVie (ABBV), and 5.2% in Merck (MRK).

Latest articles

Apple stock fell 4.6% as the US-China trade war intensified today. China warned of tariffs on more US goods, followed by Trump's tweeted response.

In response to new tariffs from China and President Trump's tweets, the market tanked to session lows on Friday. The DJIA nosedived more than 600 points.

Coverage on Cresco Labs has increased from seven analysts in July to nine in August. Six analysts favor a “strong buy,” and three recommend a “buy.”

AMD stock hit a new 13-year high after the EPYC Rome server CPU launched. How can AMD outperform Intel CPUs at such low prices and still profit?

VMware (VMW) lost about 9% in early hours trading today. VMW released its Q2 of fiscal 2020 results on August 22 after the market closed.

Since Netflix posted its Q2 results, its stock has fallen 18%. Could the streaming giant lose its disruptor position as new players enter the market?